Patent for Abbott's Norvir protease inhibitor: invention supported by NIAID contract AI27220

[James Love <love@cptech.org>]

According to the US Patent on NORVIR, a HIV protease inhibitor sold by
Abbott,
the invention was funded by NIAID grant AI27220, making the drug
subject to the US compulsory licensing provisions of 35 USC 203 (the
Bayh-Dole Act).      Jamie Love <love@cptech.org>



United States Patent    5,541,206

Kempf ,   et al.        July 30, 1996 


Retroviral protease inhibiting compounds 

Abstract

A retroviral protease inhibiting compound of the formula: ##STR1## is
disclosed. 


 Inventors: 
Kempf; Dale J. (Libertyville, IL); Norbeck; Daniel W. (Crystal Lake,
IL); Sham; Hing Leung (Gurnee, IL); Zhao; Chen (Gurnee, IL) 

 Assignee:   Abbott Laboratories (Abbott Park, IL) 
 Appl. No.:  423387
 Filed:      April 25, 1995


  [snip]


Primary Examiner: Fan; Jane 
Attorney, Agent or Firm: Crowley; Steven R. 

        Goverment Interests


This invention was made with Government support under contract number
AI27220 awarded by the National Institute of Allergy and Infectious
Diseases. The Government has certain rights in this invention. 

  [snip]

-- 
James Love, Director, Consumer Project on Technology
I can be reached at love@cptech.org, by telephone 202.387.8030,
by fax at 202.234.5176. CPT web page is http://www.cptech.org